The UK pharmaceutical sector is evaluating supply opportunities from the Chinese import surge. May’s 16.1% export increase includes pharmaceutical ingredients and products that could benefit British drug manufacturers.
Pharmaceutical companies are assessing the quality, regulatory compliance, and cost advantages of Chinese pharmaceutical supplies. The evaluation includes both active ingredients and finished products.
The challenge lies in maintaining strict quality and safety standards while benefiting from competitive pricing. Pharmaceutical supply chains require exceptional reliability and regulatory compliance.
The pharmaceutical sector’s approach to Chinese supplies will influence drug costs, availability, and manufacturing competitiveness. Effective management could improve healthcare affordability while maintaining safety standards.